Journal
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 10, Issue 10, Pages 2789-2794Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/hv.29635
Keywords
palivizumab; serum palivizumab level; respiratory syncytial virus; pediatric intensive care unit; IMpact-RSV study; RSV-related hospitalization; severe RSV disease; BPD; bronchopulmonary dysplasia; DOMV; duration of mechanical ventilation; GA; gestational age; IgG; immunoglobulin G; MV; mechanical ventilation; NA; not applicable; PICU; pediatric intensive care unit; PICU-LOS; length of stay in the PICU; ROC; receiver operating characteristic; RSV; respiratory syncytial virus; RSVH; RSV-related hospitalization; RSVH-LOS; length of stay for RSV-related hospitalization; SD; standard deviation
Categories
Funding
- MedImmune
Ask authors/readers for more resources
Monthly doses of palivizumab, an RSV-specific monoclonal antibody, reduce RSV-related hospitalizations (RSVH) in high-risk children; however, no specific palivizumab level has been correlated with disease severity in humans. A post hoc analysis of a previous randomized, placebo-controlled trial evaluated the relationship between serum palivizumab level at the time of RSVH and disease severity. Pediatric intensive care unit (PICU) admission was the primary severity marker. Relationships were evaluated between disease severity and gestational age, age at enrollment, age at RSVH, presence of bronchopulmonary dysplasia, sex, race, multiple birth, household smoking, daycare attendance, sibling(s), family history of atopy, duration between most recent palivizumab dose and RSVH, and palivizumab level at RSVH. Forty-two (87.5%) of 48 palivizumab recipients with RSVH had palivizumab levels drawn; 11 were admitted to the PICU. Mean palivizumab levels were lower in PICU-admitted subjects (47.2g/mL) vs. non-PICU subjects (98.7g/mL; P < 0.0001); there were no statistically significant differences in other variables examined. The probability of PICU admission declined with higher palivizumab levels; there were no PICU admissions with levels 92g/mL. In multivariate analyses, palivizumab level was the only independent predictor of PICU admission (P = 0.009). Palivizumab level also correlated with duration of RSVH and PICU stay, supplemental oxygen use and duration, and mechanical ventilation use and duration (P < 0.05). Higher palivizumab level was associated with decreased disease severity in high-risk infants with RSVH. Findings suggest that palivizumab level has clinical relevance, and adherence to timely monthly dosing may confer additional protection among high-risk children receiving palivizumab.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available